… the novel oral anticoagulants with the vitamin K antagonists in patients with atrial fibrillation.
We … We found that the novel oral anticoagulants significantly reduced overall mortality, …

… Oral anticoagulation (OAC) is recommended to reduce the risk of stroke associated with
nonvalvular atrial fibrillation … Warfarin is the most widely prescribed oral anticoagulant in the …

… Atrial fibrillation (AF) is a major risk factor for stroke. Currently, acetylsalicylic acid (a platelet
inhibitor) and vitamin K antagonists (VKAs; oral anticoagulants), including warfarin, are the …

… of oral anticoagulation therapy for real-world atrial fibrillation patients with an elevated risk
of stroke, highlighting the need for improved therapies for stroke prevention in atrial fibrillation. …

… of oral anticoagulants vs aspirin (with or without low-dose warfarin) is presented for all 6
outcomes as a hazard ratio. Hazard ratios below 1 indicate that oral anticoagulant decreases …

… This meta-analysis is the first to include data for all four new oral anticoagulants studied in …
embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk…

… In this meta-analysis of the 5 large phase III trials of novel oral anticoagulants compared
to warfarin in patients with atrial fibrillation, statistically significant reductions in the primary …

… In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists
reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, …

… Atrial fibrillation (AF) is the most common significant cardiac rhythm disorder. Oral
anticoagulation (OAC) is recommended by guidelines in the presence of a moderate to high risk of …

… , an oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have
been found to be safe and effective in reducing stroke risk in patients with atrial fibrillation. We …